Q3 Earnings Alert! Plan early for this week’s stock reports with all key data in 1 placeSee list

CARsgen Therapeutics Holdings Ltd (2171)

Hong Kong
Currency in HKD
Disclaimer
4.75
+0.25(+5.56%)
Closed
2171 Scorecard
Full Analysis
Management has been aggressively buying back shares
Unusual trading volume
Fair Value
Day's Range
4.405.19
52 wk Range
2.4811.88
Bid/Ask
4.75 / 4.74
Prev. Close
4.5
Open
4.67
Day's Range
4.4-5.19
52 wk Range
2.48-11.88
Volume
20,524,000
Average Volume (3m)
3,998,777
1-Year Change
-49.47%
Fair Value
Unlock
Fair Value Upside
Unlock
2171 Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
6.28
Upside
+32.21%
Members' Sentiments
Bearish
Bullish
ProTips
Holds more cash than debt on its balance sheet
Show more

CARsgen Therapeutics Holdings Company Profile

CARsgen Therapeutics Holdings Limited, an investment holding company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies and solid tumors in China and the United States. The company is developing autologous CAR-T product candidates, including CT053, which targets B-cell maturation antigen that is in pivotal Phase II/III trial for the treatment of relapsed/refractory multiple myeloma; CT041, which targets Claudin 18.2, is in Phase II/III clinical trial for gastric/gastroesophageal junction cancer and pancreatic cancer, as well as in Phase I clinical trial for gastric or pancreatic cancer; CT011, which is in Phase I clinical trial for patients with Glypican-3 positive IIIa hepatocellular carcinoma (HCC); and CT071, that is in Phase I clinical trial which targets G protein-coupled receptor class C group 5 member D for the treatment of R/R MM and relapsed/refractory primary plasma cell leukemia (R/R pPCL). It is also developing CT0180 and CT0181, which targets Glypican-3 that is in Phase I clinical trial for the treatment of hepatocellular carcinoma. In addition, the company is developing CT0590, which targets B-cell maturation antigen that is in Phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; CT048, which targets Claudin 18.2 that is in Phase I clinical trial for the treatment of gastric/gastroesophageal junction and pancreatic cancer; KJC2113 that targets mesothelin, as well as KJ-C2114 that are in pre-clinical stage for the treatment of solid tumors; and KJ-C2320 for acute myeloid leukemia that is in pre-clinical stage. Further, it develops AB011, which is in Phase I clinical trial for the treatment of gastric/pancreatic cancer. The company has a license agreement with HK Inno.N Corporation to develop and commercialize CT032 for the treatment of CD19. The company was founded in 2014 and is headquartered in Shanghai, China.

Compare 2171 to Peers and Sector

Metrics to compare
2171
Peers
Sector
Relationship
P/E Ratio
−3.4x−8.5x−0.6x
PEG Ratio
−0.14−0.170.00
Price/Book
1.6x3.5x2.6x
Price / LTM Sales
374.7x15.9x3.2x
Upside (Analyst Target)
45.3%4.6%43.9%
Fair Value Upside
Unlock17.4%7.8%Unlock

FAQ

What Is the CARsgen Therapeutics Holdings (2171) Stock Price Today?

The CARsgen Therapeutics Holdings stock price today is 4.75.

What Stock Exchange Does CARsgen Therapeutics Holdings Trade On?

CARsgen Therapeutics Holdings is listed and trades on the Hong Kong stock exchange.

What Is the Stock Symbol for CARsgen Therapeutics Holdings?

The stock symbol for CARsgen Therapeutics Holdings is "2171."

What Is the CARsgen Therapeutics Holdings Market Cap?

As of today, CARsgen Therapeutics Holdings market cap is 2.61B.

What is CARsgen Therapeutics Holdings Earnings Per Share?

The CARsgen Therapeutics Holdings EPS is -1.25.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.